Skip to main content
SpringerLink
Log in

The Role of Stereotactic Body Radiotherapy in the Management of Non-Small Cell Lung Cancer: An Emerging Standard for the Medically Inoperable Patient?

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The standard of care for early-stage lung cancer is surgical resection. Many patients with this diagnosis have comorbidities that preclude oncologic resection. Randomized data show that limited resection is inadequate for local disease control and may negatively impact on survival. Stereotactic body radiotherapy (SBRT) has emerged as a novel radiation modality with significant applications in the inoperable, early-stage lung cancer population. Retrospective and prospective studies published in the past decade have established the feasibility, safety, and efficacy of SBRT in these patients using a variety of dose regimens and technologies. To date, lung SBRT results demonstrate excellent local control with very little acute toxicity, and suggest improved overall survival compared to historical controls of fractionated radiotherapy. Ongoing prospective trials are exploring dose and fractionation schedules in the inoperable population, and are starting to explore the role of SBRT for the operable patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hansen H: Introduction. In Lung Cancer Therapy Annual, edn 6. Edited by Hansen H. New York: Informa Health Care; 2009:1–6.

    Google Scholar 

  2. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225–249.

    Article  PubMed  Google Scholar 

  3. Hansen H: Histopathology. In Lung Cancer Therapy Annual, edn 6. Edited by Hansen H. New York: Informa Health Care; 2009:45–56.

    Google Scholar 

  4. Juettner-Smolle FM LJ, Matzi V, Neubock N: Resection in stage I/II non-small cell lung cancer. In Controversies in the Treatment of Lung Cancer. Edited by Karger JH. Basel, Switzerland: 2010:71–77.

  5. Little AG, Rusch VW, Bonner JA, et al.: Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005, 80:2051–2056.

    Article  PubMed  Google Scholar 

  6. McGarry RC, Song G, des Rosiers P, Timmerman R: Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2002, 121:1155–1158.

    Article  PubMed  Google Scholar 

  7. Jensik RJ, Faber LP, Milloy FJ, Monson DO: Segmental resection for lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg 1973, 66:563–572.

    CAS  PubMed  Google Scholar 

  8. Sibley GS: Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma: smaller volumes and higher doses—a review. Cancer 1998, 82:433–438.

    Article  CAS  PubMed  Google Scholar 

  9. Ginsberg RJ, Rubinstein LV: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995, 60:615–622.

    Article  CAS  PubMed  Google Scholar 

  10. Miller JI, Hatcher CR Jr: Limited resection of bronchogenic carcinoma in the patient with marked impairment of pulmonary function. Ann Thorac Surg 1987, 44:340–343.

    Article  CAS  PubMed  Google Scholar 

  11. Shennib H, Bogart J, Herndon JE, et al.: Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J Thorac Cardiovasc Surg 2005, 129:813–818.

    Article  PubMed  Google Scholar 

  12. Santos R, Colonias A, Parda D, et al.: Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with stage I non-small-cell lung cancer. Surgery 2003, 134:691–697; discussion 697.

    Article  PubMed  Google Scholar 

  13. McKenna RJ Jr, Mahtabifard A, Yap J, et al.: Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function. Ann Thorac Surg 2008, 85:S733–S736.

    Article  PubMed  Google Scholar 

  14. Allen MS, Darling GE, Pechet TT, et al.: Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006, 81:1013–1019; discussion 1019–1020.

    Article  PubMed  Google Scholar 

  15. Qiao X, Tullgren O, Lax I, et al.: The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003, 41:1–11.

    Article  PubMed  Google Scholar 

  16. Zierhut D, Bettscheider C, Schubert K, et al.: Radiation therapy of stage I and II non-small cell lung cancer (NSCLC). Lung Cancer 2001, 34(Suppl 3):S39–S43.

    Article  PubMed  Google Scholar 

  17. Martel MK, Ten Haken RK, Hazuka MB, et al.: Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999, 24:31–37.

    Article  CAS  PubMed  Google Scholar 

  18. Saunders M, Dische S, Barrett A, et al.: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997, 350:161–165.

    Article  CAS  PubMed  Google Scholar 

  19. Perez CA, Pajak TF, Rubin P, et al.: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987, 59:1874–1881.

    Article  CAS  PubMed  Google Scholar 

  20. Song DY, Kavanagh BD, Benedict SH, Schefter T: Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology 2004, 18:1419–1430; discussion 1430–1432.

    PubMed  Google Scholar 

  21. Lax I, Blomgren H, Naslund I, Svanstrom R: Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994, 33:677–683.

    Article  CAS  PubMed  Google Scholar 

  22. Nagata Y, Takayama K, Matsuo Y, et al.: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427–1431.

    Article  PubMed  Google Scholar 

  23. •• Onishi H, Shirato H, Nagata Y, et al.: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2:S94–S100. This is a large series of patients with long-term follow-up treated in Japan with excellent documentation of outcomes, patterns of failure, and dose response. It demonstrates safety of the treatment of central tumors with risk-adapted doses. It also includes a group of medically operable patients who elected SBRT over surgery and have outcomes equivalent to surgical patients at this point.

    Article  PubMed  Google Scholar 

  24. Uematsu M, Shioda A, Suda A, et al.: Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001, 51:666–670.

    CAS  PubMed  Google Scholar 

  25. Baumann P, Nyman J, Lax I, et al.: Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006, 45:787–795.

    Article  PubMed  Google Scholar 

  26. Guckenberger M, Wulf J, Mueller G, et al.: Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009, 74:47–54.

    PubMed  Google Scholar 

  27. • Lagerwaard FJ, Haasbeek CJ, Smit EF, et al.: Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:685–692. Along with Guckenberger et al. [26], this is one of several large European series with reported long–term outcomes.

    PubMed  Google Scholar 

  28. Wulf J, Baier K, Mueller G, Flentje MP: Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005, 77:83–87.

    Article  PubMed  Google Scholar 

  29. •• Fakiris AJ, McGarry RC, Yiannoutsos CT, et al.: Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009, 75:677–682. This reports the updated results of the prospective phase II Indiana University [30] series showing long-term outcomes using the United States standard of 60 Gy in three fractions. The initial series demonstrated the safety and efficacy of this regimen for peripheral tumors while cautioning that this dose should not be used for centrally located lesions.

    PubMed  Google Scholar 

  30. Timmerman R, McGarry R, Yiannoutsos C, et al.: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833–4839.

    Article  PubMed  Google Scholar 

  31. Timmerman R, Papiez L, McGarry R, et al.: Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124:1946–1955.

    Article  PubMed  Google Scholar 

  32. Fowler JF, Tome WA, Fenwick JD, Mehta MP: A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004, 60:1241–1256.

    Article  PubMed  Google Scholar 

  33. • Stephans KL, Djemil T, Reddy CA, et al.: A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol 2009, 4:976–982. This is a retrospective series suggesting similar early rates of local control between 60 Gy in three fractions and 50 Gy in five fractions.

    Article  PubMed  Google Scholar 

  34. Haasbeek CJ, Lagerwaard FJ, de Jaeger K, et al.: Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer 2009, 115:587–594.

    Article  PubMed  Google Scholar 

  35. Haasbeek CJ, Lagerwaard FJ, Antonisse ME, et al.: Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 2010, 116:406–414.

    Article  PubMed  Google Scholar 

  36. •• Timmerman R, Paulus R, Galvin J, et al.: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070–1076. This is a critical report of the outcomes of stereotactic radiation using the US standard for peripheral lesions (60 Gy in three fractions), demonstrating excellent outcomes and safety in a multi-institutional setting.

    Article  CAS  PubMed  Google Scholar 

  37. • Bradley J: Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2007, 2:S118–S124. This is an excellent review of post-treatment radiographic changes to assist in image interpretation.

    Article  PubMed  Google Scholar 

  38. Takeda A, Kunieda E, Takeda T, et al.: Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:1057–1065.

    PubMed  Google Scholar 

  39. • Henderson MA, Hoopes DJ, Fletcher JW, et al.: A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:789–795. Prospectively collected data on serial PET changes following stereotactic treatment.

    PubMed  Google Scholar 

  40. Chang JY, Roth JA: Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin 2007, 17:251–259.

    Article  PubMed  Google Scholar 

  41. Henderson M, McGarry R, Yiannoutsos C, et al.: Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 72:404–409.

    PubMed  Google Scholar 

  42. Stephans KL, Djemil T, Reddy CA, et al.: Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009, 4:838–844.

    Article  PubMed  Google Scholar 

  43. • Dunlap NE, Cai J, Biedermann GB, et al.: Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:796–801. This is an early report of planning parameters to aide in reduction of chest wall toxicity.

    PubMed  Google Scholar 

  44. Pettersson N, Nyman J, Johansson KA: Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol 2009, 91:360–368.

    Article  PubMed  Google Scholar 

  45. Kawase T, Takeda A, Kunieda E, et al.: Extrapulmonary soft-tissue fibrosis resulting from hypofractionated stereotactic body radiotherapy for pulmonary nodular lesions. Int J Radiat Oncol Biol Phys 2009, 74:349–354.

    PubMed  Google Scholar 

  46. Hoppe BS, Laser B, Kowalski AV, et al.: Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol Biol Phys 2008, 72:1283–1286.

    PubMed  Google Scholar 

  47. Forquer JA, Fakiris AJ, Timmerman RD, et al.: Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009, 93:408–413.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Cleveland Clinic Lerner College of Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Mailroom T28, Cleveland, OH, 44195, USA

    Gregory M. M. Videtic

  2. Department of Radiation Oncology, The Cleveland Clinic, 9500 Euclid Avenue, Mailroom T28, Cleveland, OH, 44195, USA

    Gregory M. M. Videtic & Kevin L. Stephans

Authors
  1. Gregory M. M. Videtic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin L. Stephans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory M. M. Videtic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Videtic, G.M.M., Stephans, K.L. The Role of Stereotactic Body Radiotherapy in the Management of Non-Small Cell Lung Cancer: An Emerging Standard for the Medically Inoperable Patient?. Curr Oncol Rep 12, 235–241 (2010). https://doi.org/10.1007/s11912-010-0108-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-010-0108-1

Keywords

Search

Navigation